Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on February 18, 2005. The filing reports the entry into a Material Definitive Agreement on February 16, 2005, with Avid Bioservices, Inc. regarding the commercial supply of a recombinant human enzyme.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than periodic financial performance.
Material Changes and Agreement Details
- Agreement Type: Commercial Supply Agreement with Avid Bioservices, Inc.
- Scope: Avid will manufacture Halozyme's first recombinant human enzyme under current good manufacturing practice (cGMP) on a non-exclusive basis.
- Duration: The agreement covers a period of two years.
- Capacity: Avid is contracted to produce up to seven batches of the enzyme per year.
- Application: The enzyme is intended for use in Cumulase and Enhanze SC, Halozyme's first two product candidates, as well as other products in development.
- Timeline: Manufacturing is anticipated to begin in early March 2005.
Guidance, Outlook, and Risks
Management commentary indicates the commencement of the next phase of manufacturing in early March 2005. The filing notes that confidential treatment has been requested for portions of the agreement, which have been omitted from the public text. No specific financial guidance or risk factors beyond the standard contractual nature are detailed in this summary.
Investor Verification Checklist
- Review the full text of the Commercial Supply Agreement (Exhibit 10.1) to understand omitted confidential terms.
- Verify the press release (Exhibit 99.1) for additional context on the partnership.
- Confirm the status of the Cumulase and Enhanze SC product candidates in subsequent filings.
- Monitor future reports for actual manufacturing output against the seven-batch annual capacity.